BioSpace News Archive

Establishment Labs Holdings Inc. announced that it has surpassed three million Motiva ® devices in market.

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today reported that its partner Biogen presented new Phase 1b clinical data showing that IONIS-MAPTRx (BIIB080) reduced soluble tau protein in cerebrospinal fluid (CSF) in a dose-dependent and sustained manner in patients with early-stage Alzheimer’s disease (AD).

The Janssen Pharmaceutical Companies of Johnson & Johnson disclosed that following a review of its portfolio to prioritize the most transformational assets for ongoing investment, and an assessment of the respiratory syncytial virus vaccine landscape, the Company will exit its investigational RSV adult vaccine program and discontinue its Phase 3 EVERGREEN study.

Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that management will participate in a fireside chat at the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference on Thursday, March 30th at 11:30 am ET.

Allergan Aesthetics, an AbbVie company, will be showcasing its customer-centric ‘Discover Your 360°' approach to aesthetics at the 21st Anti-Aging and Aesthetics Medicine World Congress in Monaco from 30 March - 1 April 2023, supporting practitioners to help patients ‘unlock their individuality’ in an evolving world.

Today, the U.S. Food and Drug Administration approved Narcan, 4 milligram (mg) naloxone hydrochloride nasal spray for over-the-counter (OTC), nonprescription, use – the first naloxone product approved for use without a prescription.

Medical technology company Scivita Medical Technology Co., Ltd. (‘Scivita Medical’) and Boston Scientific (NYSE: BSX), one of the leading medical technology companies worldwide, have officially signed a Strategic Agreement for Scivita’s Single-Use Percutaneous Choledochoscope.

Applied DNA Sciences, Inc. today announced that it has established a new high bar for the production of DNA with the manufacture and shipment of a multi-gram quantity of linearDNA™ in under six weeks.

Vaso Corporation (“Vaso”) (OTCQB:VASO) today announced its operating results for the three months and year ended December 31, 2022.

Today, the Cystic Fibrosis Foundation announced that Kathryn Brown will join the organization as its next Chief Communications and Marketing Officer.